2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy

BACKGROUND: Delafloxacin, a fluoroquinolone antibiotic with Gram-negative and Gram-positive activity including MRSA, was approved for treatment of ABSSSI. In a phase 3 ABSSSI trial, DLX was non-inferior to VAN/AZ in both objective and clinical response endpoints. Clinical signs and symptoms (S&S...

Descripción completa

Detalles Bibliográficos
Autores principales: Pullman, John, O’Riordan, William, Lawrence, Laura, Quintas, Megan, Tseng, Carol, Cammarata, Sue K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255012/
http://dx.doi.org/10.1093/ofid/ofy210.2031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255012/
http://dx.doi.org/10.1093/ofid/ofy210.2031

Ejemplares similares